Mustang Bio Shares Surge After Reverse Stock Split

Introduction

Mustang Bio, Inc. (NASDAQ: MBIO) is a clinical-stage biopharmaceutical company headquartered in Worcester, Massachusetts. Trading under the ticker MBIO on the Nasdaq Stock Market, the company focuses on translating advancements in cell and gene therapies into potential treatments for difficult-to-treat cancers and rare genetic diseases. As of July 7, 2025, Mustang Bio’s shares closed at $2.45, reflecting a 105.88 percent increase from the previous trading day on a volume of 12,218,301 shares.

Corporate Structure

Founded by Fortress Biotech, Inc. (NASDAQ: FBIO), Mustang Bio operates as a public company registered under the Securities Exchange Act of 1934. The organization employs between 51 and 200 staff members and partners with leading medical institutions to advance its CAR-T and viral therapy platforms. Mustang’s common stock carries a par value of $0.0001 per share.

Biopharmaceutical by Melany @ tuinfosalud.com

Recent Developments and News

On January 14, 2025, Mustang Bio announced a 1-for-50 reverse stock split approved by its board and stockholders on June 27, 2024. The split became effective at the open of trading on January 16, 2025, reducing outstanding shares from approximately 64.8 million to about 1.3 million and ensuring compliance with Nasdaq’s $1.00 minimum bid price requirement.
In May 2023, Mustang entered into a strategic manufacturing partnership with uBriGene (Boston) Biosciences, selling its Worcester facility for up to $11 million and securing ongoing manufacturing support for MB-106 and future pipeline candidates.
On May 14, 2025, Mustang filed its Quarterly Report on Form 10-Q, and on May 15, 2025, it amended a Schedule 13G to disclose that Armistice Capital, LLC held 129,213 shares, representing 4.99 percent of the outstanding common stock as of the filing date.

Financial and Strategic Analysis

Mustang Bio’s share price increase to $2.45 on July 7, 2025, reflects heightened trading activity following the reverse split and anticipation of forthcoming data readouts. Clinical-stage biopharmaceutical companies often report net losses while funding multi-center trials; the sale of its manufacturing facility and partnership with uBriGene are anticipated to reduce annual operating and interest expenses by at least $28 million. The company is expected to benefit from cash proceeds resulting from equity raises and licensing agreements, and its strategic focus remains on advancing lead programs through regulatory filings and pivotal data milestones.

Market Position and Industry Context

Operating in the biotechnology research sector, Mustang Bio develops CAR-T therapies targeting hematologic cancers and solid tumors, as well as oncolytic viruses and in vivo CAR-T platforms. Its CD20-directed candidate MB-106 is in a physician-IND trial for B-cell non-Hodgkin lymphoma, an indication with an estimated 74,680 new U.S. cases in 2018 and a 70 percent five-year survival rate. MB-101 targets IL-13Rα2 in glioblastoma multiforme, which has approximately 30,000 annual diagnoses globally and a five-year survival rate of 5 percent. The C134 oncolytic herpes simplex virus and the MB-109 combination program further diversify Mustang’s pipeline. Partnerships with City of Hope, nationwide children's hospital, and the Mayo Clinic, among other leading institutions, position Mustang within a competitive landscape focused on next-generation cell and gene therapies.

tl;dr

As of July 7, 2025, Mustang Bio’s shares increased by 105.88 percent to $2.45 on heavy volume. The company executed a 1-for-50 reverse stock split on January 16, 2025, to meet Nasdaq requirements. Key ongoing programs include MB-106 for B-cell NHL and MB-101/MB-109 for glioblastoma. Mustang’s strategic manufacturing partnership with uBriGene and asset sale are projected to reduce annual expenses by at least $28 million. Armistice Capital holds 4.99 percent of the stock, and upcoming clinical data and regulatory filings are primary catalysts for the near-term outlook.